Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN-Reference-Cited by-同舟云学术

Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

Published:2022-02 Issue:2 Volume:81 Page:184-192
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Saad Fred,Small Eric J.,Feng Felix Y.,Graff Julie N.,Olmos David,Hadaschik Boris A.,Oudard Stéphane,Londhe Anil,Bhaumik Amitabha,Lopez-Gitlitz Angela,Thomas Shibu,Mundle Suneel D.,Chowdhury Simon,Smith Matthew R.

Publisher

Elsevier BV

Subject

Urology

Reference25 articles.

1. Association of prostate specific-antigen doubling time (PSADT) with metastasis-free survival (MFS) and overall survival (OS) in non-metastatic castration-resistant prostate cancer (nmCRPC);Lin;J Clin Oncol,2017

2. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time;Smith;J Clin Oncol,2013

3. Darolutamide in nonmetastatic, castration-resistant prostate cancer;Fizazi;N Engl J Med,2019

4. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer;Hussain;N Engl J Med,2018

5. Apalutamide treatment and metastasis-free survival in prostate cancer;Smith;N Engl J Med,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study;Journal of Cancer Research and Clinical Oncology;2024-09-09

2. Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race;ClinicoEconomics and Outcomes Research;2024-09

3. Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis;European Urology Oncology;2024-08

4. PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC);Clinical and Translational Oncology;2024-07-29

5. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients;The Prostate;2024-05-29